Literature DB >> 15908747

Diagnostic value of FDG-PET and HMPAO-SPET in patients with mild dementia and mild cognitive impairment: metabolic index and perfusion index.

Natascha Döbert1, Johannes Pantel, Lutz Frölich, Nadja Hamscho, Christian Menzel, Frank Grünwald.   

Abstract

OBJECTIVE: The diagnostic potential of F-18-2-fluoro-2-deoxy-D-glucose positron emission tomography (PET) and technetium-99m hexamethylpropylene amine oxime single-photon emission tomography (SPET) in early detection and differential diagnosis of early dementia was evaluated including a comparison of metabolic and perfusion indices (PI).
METHODS: Twenty-four patients with initial clinical suspicion of beginning dementia were examined, 12 of them with mild cognitive impairment. All patients underwent SPET and PET within 2 weeks. Data were compared with the final clinical diagnosis at follow-up - 9 with Alzheimer's disease (AD), 1 with frontotemporal dementia, 1 with vascular dementia (VD), 7 with mixed type of dementia (MIX) and 6 without any type of dementia. Metabolic indices (MI) and PI were compared with each other. The regional cerebral blood flow difference (rCBFdiff) calculated as local uptake difference between the right and left hemisphere was measured for patients with VD and MIX.
RESULTS: PET showed higher sensitivity and specificity in identifying the different types of early dementia (44--91 and 78--89%, respectively) than SPET (11--64 and 79--89%, respectively), especially in detecting AD (sensitivity 44%, specificity 83%) and MIX (sensitivity 71%, specificity 78%). Especially in patients with mild cognitive impairment, PET was the superior imaging modality for predicting dementia. Using PET, dementia could be excluded in all patients who did not develop dementia during the follow-up. In all patients, a weak correlation between PI and MI was observed (rho=0.64, p<0.002). The rCBFdiff in patients with VD and MIX ranged from 7 to 37%.
CONCLUSION: In this study on patients with initial suspicion of beginning dementia who underwent both imaging modalities, PET and SPET, PET was the superior imaging method, especially in the detection of early AD or MIX. Copyright (c) 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15908747     DOI: 10.1159/000085857

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  10 in total

1.  PET is better than perfusion SPECT for early diagnosis of Alzheimer's disease -- against.

Authors:  Alberto Pupi; Flavio Mariano Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12       Impact factor: 9.236

2.  PET is better than perfusion SPECT for early diagnosis of Alzheimer's disease -- for.

Authors:  Kazunari Ishii; Satoshi Minoshima
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12       Impact factor: 9.236

Review 3.  Clinical utility of FDG-PET for the clinical diagnosis in MCI.

Authors:  Javier Arbizu; Cristina Festari; Daniele Altomare; Zuzana Walker; Femke Bouwman; Jasmine Rivolta; Stefania Orini; Henryk Barthel; Federica Agosta; Alexander Drzezga; Peter Nestor; Marina Boccardi; Giovanni Battista Frisoni; Flavio Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-04-27       Impact factor: 9.236

4.  Chronic cerebral hypoperfusion in male rats results in sustained HPA activation and hyperinsulinemia.

Authors:  Theresa A Lansdell; Anne M Dorrance
Journal:  Am J Physiol Endocrinol Metab       Date:  2021-11-08       Impact factor: 4.310

5.  Functional brain imaging: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2006-12-01

6.  Fluorodeoxyglucose-positron emission tomography in the differential diagnosis of early-onset dementia: a prospective, community-based study.

Authors:  Peter K Panegyres; Jeffrey M Rogers; Michael McCarthy; Andrew Campbell; Jing Shan Wu
Journal:  BMC Neurol       Date:  2009-08-12       Impact factor: 2.474

Review 7.  Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders.

Authors:  Simon Ducharme; Annemiek Dols; Robert Laforce; Emma Devenney; Fiona Kumfor; Jan van den Stock; Caroline Dallaire-Théroux; Harro Seelaar; Flora Gossink; Everard Vijverberg; Edward Huey; Mathieu Vandenbulcke; Mario Masellis; Calvin Trieu; Chiadi Onyike; Paulo Caramelli; Leonardo Cruz de Souza; Alexander Santillo; Maria Landqvist Waldö; Ramon Landin-Romero; Olivier Piguet; Wendy Kelso; Dhamidhu Eratne; Dennis Velakoulis; Manabu Ikeda; David Perry; Peter Pressman; Bradley Boeve; Rik Vandenberghe; Mario Mendez; Carole Azuar; Richard Levy; Isabelle Le Ber; Sandra Baez; Alan Lerner; Ratnavalli Ellajosyula; Florence Pasquier; Daniela Galimberti; Elio Scarpini; John van Swieten; Michael Hornberger; Howard Rosen; John Hodges; Janine Diehl-Schmid; Yolande Pijnenburg
Journal:  Brain       Date:  2020-06-01       Impact factor: 13.501

Review 8.  Brain SPECT as a Biomarker of Neurodegeneration in Dementia in the Era of Molecular Imaging: Still a Valid Option?

Authors:  Rodolfo Ferrando; Andres Damian
Journal:  Front Neurol       Date:  2021-05-10       Impact factor: 4.003

9.  Direct comparison study between FDG-PET and IMP-SPECT for diagnosing Alzheimer's disease using 3D-SSP analysis in the same patients.

Authors:  Takashi Nihashi; Hiroshi Yatsuya; Kazumasa Hayasaka; Rikio Kato; Shoji Kawatsu; Yutaka Arahata; Katsushige Iwai; Akinori Takeda; Yukihiko Washimi; Kumiko Yoshimura; Kanako Mizuno; Takashi Kato; Shinji Naganawa; Kengo Ito
Journal:  Radiat Med       Date:  2007-07-27

Review 10.  Biological markers for early detection and pharmacological treatment of Alzheimer's disease.

Authors:  Harald Hampel; Karl Broich; Yvonne Hoessler; Johannes Pantel
Journal:  Dialogues Clin Neurosci       Date:  2009       Impact factor: 5.986

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.